An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.
Dr. Edward Garon, director of thoracic oncology at UCLA's Jonsson Comprehensive Cancer Center, presented the preliminary results of a Phase 1B study of the new drug, called MK-3475, on Oct. 29 at the World Conference on Lung Cancer in Sydney, Australia.
The detailed interim data on safety and activity came from a cohort of 38 patients with non-small cell lung cancer who were treated previously for the disease without positive results. For the study, the patients received MK-3475 every three weeks.
Among the participants, 24 percent responded to the drug, with their tumors shrinking, and the median overall survival rate was 51 weeks. For those who responded, the median response duration the average amount of time their tumors remained shrunk had not been reached at the time of this analysis, so it is at least 62 weeks.
Based on this data, a Phase 2/3 trial comparing two different doses of MK-3475 to standard chemotherapy for lung cancer has begun enrolling patients.
Some cancer cells can evade detection by the immune system by expressing a protein called PD-L1, which interacts with the protein PD-1 to prevent the immune system from seeing the cancer as an invader. MK-3475, an anti-PD-1 immunotherapy drug made by Merck, allows the immune system to properly detect the cancer and to activate T cells the so-called "foot soldiers" of the immune system to attack and kill cancer cells.
The most commonly reported drug-related side effects in the study were rash (21 percent), skin itching (18 percent), fatigue (16 percent), diarrhea (13 percent) and joint pain (11 percent). Most side effects, however, were of low grade.
"These are early results,
|Contact: Shaun Mason|
University of California - Los Angeles